StockData
MaxCyte, Inc. logo

MaxCyte, Inc. (MXCT) income statement

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3062% below fair value
$1.19+0.00 (0.00%)

Close on Nov 13, 2026Market cap $122.82MP/E –Yield –

MaxCyte, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
81.0%
Operating margin
-98.0%
Net margin
-81.4%
Return on equity, FY2025
-23.6%

Financial strength

Current ratio
7.83
Debt to equity
–
Debt to assets
–
Cash to current liabilities
84.0%

Valuation

P/E ratio
–
Price to sales
3.57
Price to book
0.81
Dividend yield
–

See a number that looks wrong?